Atorvastatin Treatment for Men with Lower Urinary Tract Symptoms and Benign Prostatic Enlargement

European Urology

Volumn 52, Issue 2, 2007, Pages 503-509

  Mills, Ian W ^a   Crossland, Anna ^a   Patel, Anup ^b   Ramonas, Henrikas ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Atorvastatin; Benign prostatic enlargement; Benign prostatic hyperplasia; Lower urinary tract symptoms; Prostate; PSA

Indexed keywords

ATORVASTATIN; LIPID; LOW DENSITY LIPOPROTEIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GASTRITIS; HUMAN; INFLUENZA; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIPID BLOOD LEVEL; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORGAN SIZE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; URINE FLOW RATE; VOMITING;

AGED; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PYRROLES; QUALITY OF LIFE; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 34250721160     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.02.032     Document Type: Article

References (26)

1. Hutchison A., Farmer R., Verhamme K., et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 51 (2007) 207-216
2. van Exel N.J., Koopmanschap M.A., McDonnell J., et al. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 49 (2006) 92-102
3. Mirone V., Imbimbo C., Longo N., and Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol 51 (2007) 57-66
4. Novara G., Galfano A., Ficarra V., and Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 50 (2006) 675-683
5. Amarenco P., Bogousslavsky J., Callahan III A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
6. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
7. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
8. Ridker P.M., Morrow D.A., Rose L.M., et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45 (2005) 1644-1648
9. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
10. Rees R.W., Foxwell N.A., Ralph D.J., et al. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 170 (2003) 2517-2522
11. Watts K.L., and Spiteri M.A. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 287 (2004) L1323-L1332
12. Padayatty S.J., Marcelli M., Shao T.C., et al. Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab 82 (1997) 1434-1439
13. Sotiriou C.G., and Cheng J.W. Beneficial effects of statins in coronary artery disease-beyond lowering cholesterol. Ann Pharmacother 34 (2000) 1432-1439
14. Sivaprasad U., Abbas T., and Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 5 (2006) 2310-2316
15. Mitropoulos D., Ploumidou K., Kyroudi-Voulgari A., et al. Hypercholesterol diet alters serum lipid profile and ventral prostate structure in rats. Eur Urol Suppl 2 1 (2003) 20
16. Hammarsten J., and Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39 (2001) 151-158
17. Rohrmann S., Smit E., Giovannucci E., et al. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 29 (2005) 310-316
18. Marino G., Pugno E., Cevoli R., et al. Pharmacologic treatment of benign prostatic hypertrophy (BPH): a combination of mepartricin and simvastatin. Analysis and results. Minerva Urol Nefrol 43 (1991) 279-282
19. Desgrandchamps F. Importance of individual response in symptom score evaluation. Eur Urol 40 Suppl 3 (2001) 2-7
20. Jones P., Kafonek S., Laurora I., et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
21. Martineau P., Gaw A., de Teresa E., et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 191 (2007) 135-146
22. Ekman P. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group. Eur Urol 33 (1998) 312-317
23. Herrmann H.C., Levine L.A., Macaluso Jr. J., et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 3 (2006) 303-308
24. Shannon J., Tewoderos S., Garzotto M., et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162 (2005) 318-325
25. Coogan P.F., Rosenberg L., Palmer J.R., et al. Statin use and the risk of breast and prostate cancer. Epidemiology 13 (2002) 262-267
26. Cyrus-David M.S., Weinberg A., Thompson T., et al. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 173 (2005) 1923-1925